The Manufacturers Life Insurance Company Raises Stock Position in Erasca, Inc. $ERAS

The Manufacturers Life Insurance Company boosted its holdings in shares of Erasca, Inc. (NASDAQ:ERAS) by 295.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 216,614 shares of the company’s stock after purchasing an additional 161,845 shares during the period. The Manufacturers Life Insurance Company’s holdings in Erasca were worth $3,505,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in Erasca by 58.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company’s stock worth $27,000 after purchasing an additional 7,923 shares during the period. EP Wealth Advisors LLC purchased a new position in shares of Erasca during the 2nd quarter valued at about $29,000. Russell Investments Group Ltd. acquired a new position in shares of Erasca in the 3rd quarter valued at about $31,000. EntryPoint Capital LLC acquired a new position in shares of Erasca in the 4th quarter valued at about $38,000. Finally, Stifel Financial Corp purchased a new stake in shares of Erasca in the fourth quarter worth about $38,000. 67.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on ERAS. Jefferies Financial Group reaffirmed a “buy” rating on shares of Erasca in a report on Tuesday, July 14th. Stifel Nicolaus upped their price objective on Erasca from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Wall Street Zen cut shares of Erasca from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Erasca in a research note on Thursday, June 11th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Erasca in a report on Tuesday, July 14th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $21.64.

Erasca News Roundup

Here are the key news stories impacting Erasca this week:

• Negative Sentiment: Several firms, including Hagens Berman, allege that Erasca and certain executives misled investors about the competitive advantages, safety profile and intellectual-property protection of ERAS-0015, the company’s lead oncology candidate. These are allegations, not proven findings. Hagens Berman Erasca class action alert
• Negative Sentiment: The lawsuit covers investors who purchased Erasca securities from January 14, 2025, through April 26, 2026. Continued legal notices could increase reputational, financial and disclosure risks for the biotechnology company and contribute to volatility. Bronstein Gewirtz Grossman Erasca lawsuit announcement
• Neutral Sentiment: Investors have until August 10, 2026, to apply to become lead plaintiff. The many releases issued by investor-rights firms primarily seek clients and repeat the same deadline; they do not represent new clinical, regulatory or financial information from Erasca. Kahn Swick and Foti Erasca deadline notice

Erasca Trading Up 0.8%

NASDAQ:ERAS opened at $18.41 on Friday. The stock has a 50 day moving average of $16.80 and a two-hundred day moving average of $14.73. Erasca, Inc. has a 12 month low of $1.33 and a 12 month high of $24.28. The firm has a market cap of $5.73 billion, a P/E ratio of -19.80 and a beta of 0.66.

Erasca (NASDAQ:ERAS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). On average, research analysts forecast that Erasca, Inc. will post -0.54 earnings per share for the current year.

Erasca Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.